MAGELLAN LONGEVITY
HomeResearchStudy library › Thyroid antibody status, subclinical hypothyroidism, and the risk of…
Study summary · General aging biology & healthspan

Does thyroid autoimmunity, specifically the presence of thyroid peroxidase antibodies (TPOAbs), independently affect the risk of coronary heart disease (CHD) in individuals with subclinical hypothyroidism?

In one paragraph

Thyroid, a prospective cohort study in 38,274 participants (J Clin Endocrinol Metab 2014, PMID 24915118) — among 38,274 adults, 1691 (4.4%) had subclinical hypothyroidism, with 775 (45.8%) of these having positive TPOAbs. Similarly, risks of CHD events did not differ by TPOAb status (HR 1.16 vs HR 1.26).

Source: J Clin Endocrinol Metab 2014, PMID 24915118 ↗ · Research map · How Magellan grades evidence · evidence confidence: high

J Clin Endocrinol Metab · 2014 · PMID 24915118 · DOI 10.1210/jc.2014-1250

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Thyroid antibody status does not independently predict coronary heart disease risk in individuals with subclinical hypothyroidism.

The question

Does thyroid autoimmunity, specifically the presence of thyroid peroxidase antibodies (TPOAbs), independently affect the risk of coronary heart disease (CHD) in individuals with subclinical hypothyroidism?

What they tested

The study aimed to compare the CHD risk in subclinical hypothyroidism with and without TPOAbs to determine if thyroid autoimmunity independently affects CHD risk.

How they did it

A MEDLINE and EMBASE search from 1950 to 2011 was conducted to identify prospective cohorts reporting baseline thyroid function, antibodies, and CHD outcomes. Individual data from 38,274 participants across six cohorts were analyzed for CHD mortality, and 33,394 participants from four cohorts for CHD events.

What they found

Among 38,274 adults, 1691 (4.4%) had subclinical hypothyroidism, with 775 (45.8%) of these having positive TPOAbs. Compared with euthyroid individuals, age- and gender-adjusted risks of CHD mortality in subclinical hypothyroidism were similar for those with and without TPOAbs (HR 1.15 vs HR 1.26). Similarly, risks of CHD events did not differ by TPOAb status (HR 1.16 vs HR 1.26). Risks of CHD mortality and events increased with higher thyrotropin levels, but within each thyrotropin stratum, risks did not differ by TPOAb status.

Adjusted Hazard Ratios for CHD Mortality and Events in Subclinical Hypothyroidism
Values shown: Hazard Ratio
CHD Mortality (No TPOAbs)1.15
CHD Mortality (Positive TPOAbs)1.26
CHD Events (No TPOAbs)1.16
CHD Events (Positive TPOAbs)1.26

Hazard ratios for CHD mortality and events in individuals with subclinical hypothyroidism, stratified by thyroid peroxidase antibody (TPOAb) status, compared to euthyroid individuals.

What it means

The risk of coronary heart disease associated with subclinical hypothyroidism did not differ based on thyroid peroxidase antibody status. This suggests that biomarkers of thyroid autoimmunity do not provide independent prognostic information for CHD outcomes.

Limitations

The abstract does not explicitly state any limitations of the study.

Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.

“Risks of coronary heart disease mortality and events increased with higher thyrotropin”— from the published abstract, J Clin Endocrinol Metab 2014

The paper at a glance

TitleThyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease
JournalJ Clin Endocrinol Metab
Year2014
PMID24915118 ↗
DOI10.1210/jc.2014-1250 ↗
TopicGeneral aging biology & healthspan

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Thyroid (TSH) Home Panel

Subclinical dysfunction raises coronary mortality. Research relevant to this mechanism is indexed on PubMed and linked below; it describes the mechanism rather than this specific product.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Does thyroid autoimmunity, specifically the presence of thyroid peroxidase antibodies (TPOAbs), independently affect the risk of coronary heart disease (CHD) in individuals with subclinical hypothyroidism? [Plain-English summary of J Clin Endocrinol Metab 2014, PMID 24915118, DOI 10.1210/jc.2014-1250]. Magellan Longevity. https://magellanlongevity.com/study/d24915118.html
BibTeX
@misc{magellan_d24915118, title = {Does thyroid autoimmunity, specifically the presence of thyroid peroxidase antibodies (TPOAbs), independently affect the risk of coronary heart disease (CHD) in individuals with subclinical hypothyroidism?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/d24915118.html}}, note = {Plain-English summary of PubMed PMID 24915118; DOI 10.1210/jc.2014-1250; J Clin Endocrinol Metab 2014. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/d24915118.html

Related studies in the Magellan library

All 25 Magellan summaries on general aging biology & healthspan →

How this summary was made. Every section above restates what the published abstract of PMID 24915118 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.